BRIEF—Aduro Biotech and Lilly ink research collaboration

Eli Lilly and Aduro Biotech have agreed a research and licensing deal for Aduro's cGAS-STING Pathway Inhibitor program, which seeks to develop novel immunotherapies for autoimmune and other inflammatory diseases.

Lilly will gain access to novel molecules from Aduro and the firms will work together to advance them into clinical development.

Aduro will receive $12 million up front, and up to $620 million per product in development and commercial milestones, plus single to low-double digit royalties on future sales.

Aduro has the option to co-fund the clinical development of each product in exchange for an increase in royalty payments. Lilly will be responsible for all costs of global commercialization.